RB-pathway disruption in breast cancer

References

• American Cancer Society. Cancer facts & figures 2009 2009; Atlanta, GA The American Cancer Society
   Google Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9:631 - 643
   PubMed Web of Science ®Google Scholar
• Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14:8010 - 8018
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52:108 - 118
   PubMed Web of Science ®Google Scholar
• Miller TW, Perez-Torres M, Narasanna A, Guix M, Stal O, Perez-Tenorio G, et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009; 69:4192 - 4201
   PubMed Web of Science ®Google Scholar
• Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95:353 - 361
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, et al. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 2008; 68:7493 - 7501
   PubMed Web of Science ®Google Scholar
• Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006; 1:15 - 24
   Web of Science ®Google Scholar
• Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8:671 - 682
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008; 8:714 - 724
   PubMed Web of Science ®Google Scholar
• Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005; 24:2796 - 2809
   PubMed Web of Science ®Google Scholar
• Gladden AB, Diehl JA. Location, location, location: The role of cyclin D1 nuclear localization in cancer. J Cell Biochem 2005; 96:906 - 913
   PubMed Web of Science ®Google Scholar
• Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004; 9:95 - 104
   PubMed Web of Science ®Google Scholar
• Mittnacht S. Control of pRB phosphorylation. Curr Opin Genet Dev 1998; 8:21 - 27
   PubMed Web of Science ®Google Scholar
• Markey MP, Bergseid J, Bosco EE, Stengel K, Xu H, Mayhew CN, et al. Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function. Oncogene 2007; 26:6307 - 6318
   PubMed Web of Science ®Google Scholar
• Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005; 23:4215 - 4224
   PubMed Web of Science ®Google Scholar
• Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM. Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer 1998; 79:71 - 75
   PubMed Web of Science ®Google Scholar
• Hui R, Macmillan RD, Kenny FS, Musgrove EA, Blamey RW, Nicholson RI, et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 2000; 6:2777 - 2787
   PubMed Web of Science ®Google Scholar
• Oliveira AM, Ross JS, Fletcher JA. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 2005; 124:16 - 28
   PubMedGoogle Scholar
• Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle 2007; 6:667 - 671
   PubMed Web of Science ®Google Scholar
• Markey MP, Angus SP, Strobeck MW, Williams SL, Gunawardena RW, Aronow BJ, et al. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res 2002; 62:6587 - 6597
   PubMed Web of Science ®Google Scholar
• Derenzini M, Donati G, Mazzini G, Montanaro L, Vici M, Ceccarelli C, et al. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure. Clin Cancer Res 2008; 14:2199 - 2209
   PubMed Web of Science ®Google Scholar
• Treré D, Brighenti E, Donati G, Ceccarelli C, Santini D, Taffurelli M, et al. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. Annals of Oncology 2009; 20:1818 - 1823
   PubMed Web of Science ®Google Scholar
• Burkhart DL, Ngai LK, Roake CM, Viatour P, Thangavel C, Ho VM, et al. Regulation of RB transcription in vivo by RB family members. Mol Cell Biol 30:1729 - 1745
   PubMed Web of Science ®Google Scholar
• Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, et al. E2F integrates cell cycle progression with DNA repair, replication and G(2)/M checkpoints. Genes Dev 2002; 16:245 - 256
   PubMed Web of Science ®Google Scholar
• Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M, et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001; 21:4684 - 4699
   PubMed Web of Science ®Google Scholar
• Vernell R, Helin K, Muller H. Identification of target genes of the p16INK4A-pRB-E2F pathway. J Biol Chem 2003; 278:46124 - 46137
   PubMed Web of Science ®Google Scholar
• Subhawong AP, Subhawong T, Nassar H, Kouprina N, Begum S, Vang R, et al. Most basal-like breast carcinomas demonstrate the same Rb−/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 2009; 33:163 - 175
   PubMed Web of Science ®Google Scholar
• Nielsen NH, Loden M, Cajander J, Emdin SO, Landberg G. G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res Treat 1999; 56:105 - 112
   PubMed Web of Science ®Google Scholar
• Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008; 10:75
   PubMed Web of Science ®Google Scholar
• Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007; 117:218 - 228
   PubMed Web of Science ®Google Scholar
• Stengel KR, Dean JL, Seeley SL, Mayhew CN, Knudsen ES. RB status governs differential sensitivity to cytotoxic and molecularly-targeted therapeutic agents. Cell Cycle 2008; 7:1095 - 1103
   PubMedGoogle Scholar
• Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010; 29:4018 - 4032
   PubMed Web of Science ®Google Scholar
• Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30:207 - 210
   PubMed Web of Science ®Google Scholar
• Brazma A, Parkinson H, Sarkans U, Shojatalab M, Vilo J, Abeygunawardena N, et al. ArrayExpress—a public repository for microarray gene expression data at the EBI. Nucleic Acids Res 2003; 31:68 - 71
   PubMed Web of Science ®Google Scholar
• Ertel A, Tozeren A. Human and mouse switch-like genes share common transcriptional regulatory mechanisms for bimodality. BMC Genomics 2008; 9:628
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4:249 - 264
   PubMed Web of Science ®Google Scholar
• Katz S, Irizarry RA, Lin X, Tripputi M, Porter MW. A summarization approach for Affymetrix GeneChip data using a reference training set from a large, biologically diverse database. BMC Bioinformatics 2006; 7:464
   PubMed Web of Science ®Google Scholar
• Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007; 8:203 - 211
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: tool for the unification of biology. Nat Genet 2000; 25:25 - 29
   PubMed Web of Science ®Google Scholar
• Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization and Integrated Discovery. Genome Biol 2003; 4:3
   PubMed Web of Science ®Google Scholar
• Zagorski WA, Knudsen ES, Reed MF. Retinoblastoma deficiency increases chemosensitivity in lung cancer. Cancer Res 2007; 67:8264 - 8273
   PubMed Web of Science ®Google Scholar
• Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A, et al. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res 2010; 70:1711 - 1721
   PubMed Web of Science ®Google Scholar
• Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65:4059 - 4066
   PubMed Web of Science ®Google Scholar
• Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96
   PubMed Web of Science ®Google Scholar
• Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006; 6:99 - 106
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98:262 - 272
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10:7252 - 7259
   PubMed Web of Science ®Google Scholar
• Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24:4236 - 4244
   PubMed Web of Science ®Google Scholar
• Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Desmedt C, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010; 16:214 - 218
   PubMed Web of Science ®Google Scholar